We're Not Very Worried About Genetic Signatures' (ASX:GSS) Cash Burn Rate
Jan 15
Have your own idea? Try our Stock Screener
Australian (ASX) Life Sciences Industry Analysis
UpdatedJan 19, 2026
DataAggregated Company Financials
Companies7
- 7D7.6%
- 3M12.2%
- 1Y-21.8%
- YTD4.9%
Over the last 7 days, the Life Sciences industry has risen 7.6%, driven by gains from Proteomics International Laboratories of 16%. During this same period, the Genetic Signatures underperformed, falling 6.4%. In contrast, the industry has lost 22% in the last 12 months. Earnings are forecast to grow by 70% annually.
Industry Valuation and Performance
Has the Australian Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 19 Jan 2026 | AU$469.6m | AU$206.8m | -AU$83,644,198.00 | 26.2x | -5.6x | 2.3x |
| Wed, 17 Dec 2025 | AU$409.0m | AU$206.8m | -AU$83,644,198.00 | 25.9x | -4.9x | 2x |
| Fri, 14 Nov 2025 | AU$525.7m | AU$273.6m | -AU$76,913,757.00 | 24.4x | -6.8x | 1.9x |
| Sun, 12 Oct 2025 | AU$521.2m | AU$273.6m | -AU$76,913,757.00 | 20.5x | -6.8x | 1.9x |
| Tue, 09 Sep 2025 | AU$498.0m | AU$273.6m | -AU$76,816,590.00 | 18.8x | -6.5x | 1.8x |
| Thu, 07 Aug 2025 | AU$555.1m | AU$273.7m | -AU$97,752,343.00 | 15.5x | -5.7x | 2x |
| Sat, 05 Jul 2025 | AU$434.6m | AU$272.6m | -AU$65,041,866.00 | 15.9x | -6.7x | 1.6x |
| Mon, 02 Jun 2025 | AU$414.6m | AU$272.6m | -AU$65,041,866.00 | 14.1x | -6.4x | 1.5x |
| Wed, 30 Apr 2025 | AU$404.1m | AU$272.6m | -AU$65,041,866.00 | 14x | -6.2x | 1.5x |
| Fri, 28 Mar 2025 | AU$469.2m | AU$272.6m | -AU$65,041,866.00 | 14.3x | -7.2x | 1.7x |
| Sun, 23 Feb 2025 | AU$488.2m | AU$254.0m | -AU$57,126,384.00 | 18x | -8.5x | 1.9x |
| Tue, 21 Jan 2025 | AU$556.2m | AU$253.8m | -AU$57,118,384.00 | 17x | -9.7x | 2.2x |
| Thu, 19 Dec 2024 | AU$622.1m | AU$263.5m | -AU$69,135,603.00 | 21x | -9x | 2.4x |
| Sat, 16 Nov 2024 | AU$643.7m | AU$263.5m | -AU$69,135,603.00 | 21.1x | -9.3x | 2.4x |
| Mon, 14 Oct 2024 | AU$716.3m | AU$263.5m | -AU$69,135,603.00 | 24.8x | -10.4x | 2.7x |
| Wed, 11 Sep 2024 | AU$715.5m | AU$263.3m | -AU$69,597,222.00 | 20.8x | -10.3x | 2.7x |
| Fri, 09 Aug 2024 | AU$608.1m | AU$246.1m | -AU$49,506,434.00 | 22.7x | -12.3x | 2.5x |
| Sun, 07 Jul 2024 | AU$595.1m | AU$246.1m | -AU$49,506,434.00 | 29.4x | -12x | 2.4x |
| Tue, 04 Jun 2024 | AU$538.2m | AU$246.1m | -AU$49,506,434.00 | 22.3x | -10.9x | 2.2x |
| Thu, 02 May 2024 | AU$540.3m | AU$246.1m | -AU$49,506,434.00 | 18.4x | -10.9x | 2.2x |
| Sat, 30 Mar 2024 | AU$539.1m | AU$246.1m | -AU$49,506,434.00 | 14.3x | -10.9x | 2.2x |
| Mon, 26 Feb 2024 | AU$505.1m | AU$243.2m | -AU$44,302,241.00 | 19.5x | -11.4x | 2.1x |
| Wed, 24 Jan 2024 | AU$458.8m | AU$248.2m | -AU$39,797,313.00 | 25.8x | -11.5x | 1.8x |
| Fri, 22 Dec 2023 | AU$529.2m | AU$248.6m | -AU$52,451,569.00 | 21.8x | -10.1x | 2.1x |
| Sun, 19 Nov 2023 | AU$543.8m | AU$248.6m | -AU$52,451,569.00 | 22.3x | -10.4x | 2.2x |
| Tue, 17 Oct 2023 | AU$559.1m | AU$248.6m | -AU$52,451,569.00 | 22.3x | -10.7x | 2.2x |
| Thu, 14 Sep 2023 | AU$570.6m | AU$248.6m | -AU$52,451,569.00 | 22.7x | -10.9x | 2.3x |
| Sat, 12 Aug 2023 | AU$645.3m | AU$221.5m | -AU$37,611,177.00 | 25.2x | -17.2x | 2.9x |
| Mon, 10 Jul 2023 | AU$653.0m | AU$221.5m | -AU$37,611,177.00 | 25.2x | -17.4x | 2.9x |
| Wed, 07 Jun 2023 | AU$663.9m | AU$221.5m | -AU$37,611,177.00 | 21.5x | -17.7x | 3x |
| Fri, 05 May 2023 | AU$618.2m | AU$221.5m | -AU$37,611,177.00 | 28.3x | -16.4x | 2.8x |
| Sun, 02 Apr 2023 | AU$722.0m | AU$221.7m | -AU$39,169,534.00 | 30.2x | -18.4x | 3.3x |
| Tue, 28 Feb 2023 | AU$781.1m | AU$174.6m | -AU$40,998,286.00 | 30.2x | -19.1x | 4.5x |
| Thu, 26 Jan 2023 | AU$812.7m | AU$184.6m | -AU$29,264,632.00 | 36.6x | -27.8x | 4.4x |
Price to Earnings Ratio
-27.8x
Current Industry PE
- Investors are relatively neutral on the Australian Life Sciences industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 2.3x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 3.8% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Australian Healthcare industry?
| AU Market | 1.95% | |
| Healthcare | 0.31% | |
| Life Sciences | 7.61% | |
| Clinical Research and Equipment | 7.61% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| PIQ Proteomics International Laboratories | AU$0.77 | 15.8% +AU$17.3m | 11.6% | PS38.1x | |
| VFY Vitrafy Life Sciences | AU$1.50 | 14.5% +AU$12.1m | -9.1% | PS91.4x | |
| TRJ Trajan Group Holdings | AU$0.70 | 1.4% +AU$1.5m | -27.5% | PS0.6x | |
| OSL OncoSil Medical | AU$0.92 | 5.7% +AU$944.6k | -54.0% | PS11.3x | |
| MEM Memphasys | AU$0.006 | 0% AU$194.0 | -14.3% | PS30.6x |
